ONO PHARMACEUTICAL CO., LTD.
4528小野薬品工業株式会社
Latest half-year results
First half · fiscal year to 2026-03 · filed 2025-11-06For the first half of the fiscal year to 2026-03: Revenue ¥257.1 billion (+7.0% YoY), Profit before tax ¥52.2 billion (+9.7% YoY), Net income ¥40.1 billion (+7.1% YoY).
| This period | Year on year | |
|---|---|---|
| Revenue | ¥257.1bn | +7.0% |
| Profit before tax | ¥52.2bn | +9.7% |
| Net profit to owners | ¥40.1bn | +7.1% |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4528/earnings-releases.
Financials
IFRS · consolidated · fiscal year to 2026-03-31- Revenue
- ¥515.8bn
- Net income
- ¥69.8bn
- ROE
- 8.5%
- Equity ratio
- 76.9%
- Dividend / share
- ¥80
- Employees
- 4,206
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | ¥515.8bn | ¥69.8bn | ¥1,106.5bn | ¥850.7bn | 8.5% | ¥148.49 | ¥136.8bn |
| 2025-03-31 | ¥486.9bn | ¥50.0bn | ¥1,064.0bn | ¥782.5bn | 6.4% | ¥106.55 | ¥82.5bn |
| 2024-03-31 | ¥502.7bn | ¥128.0bn | ¥913.7bn | ¥793.0bn | 16.7% | ¥266.61 | ¥110.7bn |
| 2023-03-31 | ¥447.2bn | ¥112.7bn | ¥882.4bn | ¥741.9bn | 16.1% | ¥230.85 | ¥159.6bn |
| 2022-03-31 | ¥361.4bn | ¥80.5bn | ¥739.2bn | ¥655.9bn | 12.5% | ¥162.19 | ¥61.8bn |
Indicators
Computed by us from filings · fiscal year to 2026-03-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | 8.5 | 49.1 |
| Ordinary margin | 0.1796 | 87.6 |
| Equity ratio, % | 76.9 | 86 |
| Revenue growth | 0.0594 | 54.8 |
| Net income growth | 0.394 | 70.7 |
| Operating cash flow / assets | 0.1237 | 82.9 |
Results wording balance: +0.39. Proprietary text method; it describes the wording only and does not interpret context.
Interest example: if all ¥110.4bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥552m, 0.4% of operating cash flow. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.
Via /v1/companies/4528/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4528/votingOwnership changes
All companies →- 2026-08-05
BlackRock Japan Co., Ltd. raised holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 7.82% from 6.65%.
- 2026-02-03
BlackRock Japan Co., Ltd. raised holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 6.65% from 5.40%.
- 2025-11-05
BlackRock Japan Co., Ltd. disclosed a 5.40% stake in ONO PHARMACEUTICAL CO., LTD. (4528), crossing the 5% reporting threshold.
- 2025-09-19
Sumitomo Mitsui Trust Bank,Limited cut holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 4.59% from 5.05%, below the 5% threshold.
- 2025-09-03
BlackRock Japan Co., Ltd. cut holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 4.65% from 7.69%, below the 5% threshold.
- 2024-07-29
Mitsubishi UFJ Financial Group, Inc. reduced holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 5.05% from 5.62%.
- 2024-04-03
BlackRock Japan Co., Ltd. raised holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 7.69% from 6.50%.
- 2023-07-05
BlackRock Japan Co., Ltd. raised holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 6.50% from 5.29%.
- 2023-04-19
Wellington Management Company LLP cut holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 4.76% from 5.89%, below the 5% threshold.
- 2022-11-08
Mitsubishi UFJ Financial Group, Inc. reduced holdings in ONO PHARMACEUTICAL CO., LTD. (4528) to 5.62% from 6.66%.
5% filings
Large shareholding reports on 4528| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-08-05 | BlackRock Japan Co., Ltd. | 7.82% | +1.17pt | pure investment |
| 2026-02-03 | BlackRock Japan Co., Ltd. | 6.65% | +1.25pt | pure investment |
| 2025-11-05 | BlackRock Japan Co., Ltd. | 5.40% | — | pure investment |
| 2025-09-19 | Sumitomo Mitsui Trust Bank,Limited | 4.59% | −0.46pt | strategic holding |
| 2025-09-03 | BlackRock Japan Co., Ltd. | 4.65% | −3.04pt | pure investment |
| 2024-07-29 | Mitsubishi UFJ Financial Group, Inc. | 5.05% | −0.57pt | strategic holding |
| 2024-04-03 | BlackRock Japan Co., Ltd. | 7.69% | +1.19pt | pure investment |
| 2023-07-05 | BlackRock Japan Co., Ltd. | 6.50% | +1.21pt | pure investment |
| 2023-04-19 | Wellington Management Company LLP | 4.76% | −1.13pt | — |
| 2022-11-08 | Mitsubishi UFJ Financial Group, Inc. | 5.62% | −1.04pt | strategic holding |
Cross-shareholdings
From the annual report's status of shareholdings- Listed strategic holdings
- 35 issues
- Book value
- ¥76.2bn
- Sold in the year
- ¥13.0bn 7 issues
- Bought in the year
- — — issues
- Mutual, both reports
- 33
- Held by listed cos.
- 52
| Holds | Book value | Shares vs. prior year | Mutual |
|---|---|---|---|
| SANTEN PHARMACEUTICAL CO.,LTD. 4536 | ¥11.1bn | 0.0% | both reports |
| T&D Holdings, Inc. 8795 | ¥6.7bn | 0.0% | both reports |
| Otsuka Holdings Co., Ltd. 4578 | ¥5.2bn | 0.0% | both reports |
| KIKKOMAN CORPORATION 2801 | ¥5.1bn | 0.0% | both reports |
| DAIKIN INDUSTRIES, LTD. 6367 | ¥4.4bn | -50.0% | both reports |
| CKD Corporation 6407 | ¥4.0bn | 0.0% | both reports |
| NISSIN FOODS HOLDINGS CO.,LTD. 2897 | ¥3.7bn | -33.3% | both reports |
| Shimadzu Corporation 7701 | ¥3.4bn | 0.0% | both reports |
| Nippon Shinyaku Co.,Ltd. 4516 | ¥3.2bn | 0.0% | both reports |
| OSAKA SODA CO.,LTD. 4046 | ¥3.0bn | 0.0% | both reports |
Held by: Mitsubishi UFJ Financial Group, Inc. 8306, MS&AD Insurance Group Holdings, Inc. 8725, Sumitomo Mitsui Trust Group, Inc. 8309, SANTEN PHARMACEUTICAL CO.,LTD. 4536, T&D Holdings, Inc. 8795, Sompo Holdings, Inc. 8630, KYORIN Pharmaceutical Co., Ltd. 4569, Alfresa Holdings Corporation 2784, MEDIPAL HOLDINGS CORPORATION 7459, OBAYASHI CORPORATION 1802, Nissan Chemical Corporation 4021, NISSIN FOODS HOLDINGS CO.,LTD. 2897 and 43 more
Purposes, all holdings and mutual flags via /v1/companies/4528/cross-holdings. Share changes include stock splits.
Major shareholders
As of fiscal year end 2026-03-31| Shareholder | Shares | Ratio |
|---|---|---|
| 日本マスタートラスト信託銀行株式会社(信託口) | 65,572,000 | 13.70% |
| 株式会社日本カストディ銀行(信託口) | 25,228,000 | 5.27% |
| 明治安田生命保険相互会社 | 18,594,000 | 3.88% |
| 公益財団法人小野奨学会 | 16,428,000 | 3.43% |
| 株式会社鶴鳴荘 | 16,158,000 | 3.37% |
| ＪＰモルガン証券株式会社 | 14,869,000 | 3.10% |
| 株式会社三菱ＵＦＪ銀行 | 8,640,000 | 1.80% |
| 日本マスタートラスト信託銀行株式会社 | 8,398,000 | 1.75% |
| ステート ストリート バンク アンド トラスト カンパニー 505001 | 7,298,000 | 1.52% |
| individual holder | 6,906,000 | 1.44% |
U.S. funds holding 4528
SEC Form N-PORT, reports to 2026-07-31156 U.S. funds held 40,260,546 shares worth $599.4m.
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND VANGUARD STAR FUNDS | 5,855,670 | $87.5m | 0.014% | 2026-07-31 |
| VANGUARD DEVELOPED MARKETS INDEX FUND VANGUARD TAX-MANAGED FUNDS | 3,871,806 | $56.9m | 0.018% | 2026-06-30 |
| iShares Core MSCI EAFE ETF iShares Trust | 2,754,800 | $41.2m | 0.022% | 2026-07-31 |
| BlackRock Advantage International Fund BlackRock Funds | 1,884,700 | $28.3m | 0.326% | 2026-05-29 |
| Dimensional International Value ETF Dimensional ETF Trust | 1,814,290 | $27.2m | 0.127% | 2026-07-31 |
Up to 25 funds per stock via the API.
Get this as JSON
GET /v1/companies/4528
GET /v1/companies/4528/financials
GET /v1/companies/4528/details
GET /v1/companies/4528/segments
GET /v1/companies/4528/voting
GET /v1/companies/4528/tender-offers
GET /v1/companies/4528/indicators
GET /v1/companies/4528/earnings-releases
GET /v1/events?ticker=4528
GET /v1/companies/4528/trades
GET /v1/companies/4528/cross-holdings
GET /v1/companies/4528/brief